Open an account

Inhibikase Therapeutics

IKT · NASDAQ

$1.71+$0.065 (+3.95%)TodayMarket closed ·
Prev close $1.65

About IKT

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company, which engages in development of protein kinase inhibitor therapeutics to modify the course of Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. The company is headquartered in Wilmington, Delaware and currently employs 35 full-time employees. The company went IPO on 2020-12-23. The firm is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Employees
35
Headquarters
Wilmington, Delaware
Listed
Dec 23, 2020
Sector
Health Care
Industry
Biotechnology
Website
inhibikase.com

IKT key statistics

Market cap
238.61M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
625.19K
Volume
363.43K
Open price
$1.65
High today
$1.75
Low today
$1.63
52 Week high
$2.61
52 Week low
$1.33

Inhibikase Therapeutics (IKT) at a glance

As of Oct 20, 2026, Inhibikase Therapeutics (IKT) shares are priced at $1.71, giving the company a market cap of 238.61M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.63 and $1.75. The current price is 4.9% above the day's low and 2.3% below its high.

Volume so far is 363.43K shares, below the average of 625.19K shares a day.

Over the past year Inhibikase Therapeutics has ranged from $1.33 to $2.61, and now sits 30% of the way up that range.

Inhibikase Therapeutics met or beat analyst EPS estimates in 3 of the last 8 quarters. In Q2 FY26 it reported -$0.11 per share against an estimate of -$0.1081.

The average analyst price target is $6.12, 257.9% above the current price, from 7 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

86%of 7 analyst ratings say Buy
  • Buy85.7%
  • Hold14.3%
  • Sell0.0%
Price target · 10 analystsAvg $6.12
Low
$3.03
Now
$1.71
High
$8.40

IKT earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 8 quarters, by 7.7% on average.

  1. Q3 FY24: reported -$0.65 per share against an estimate of -$0.3737
  2. Q4 FY24: reported -$0.50 per share against an estimate of -$0.0875
  3. Q1 FY25: reported -$0.17 per share against an estimate of -$0.1061
  4. Q2 FY25: reported -$0.11 per share against an estimate of -$0.0909
  5. Q3 FY25: reported -$0.13 per share against an estimate of -$0.1313
  6. Q4 FY25: reported -$0.09 per share against an estimate of -$0.1042
  7. Q1 FY26: reported -$0.10 per share against an estimate of -$0.1094
  8. Q2 FY26: reported -$0.11 per share against an estimate of -$0.1081

IKT news

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

  • 12 Health Care Stocks Moving In Thursday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Monday's Pre-Market Session

  • Press releasePRNewswire

    SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Inhibikase Therapeutics, Inc. (NASDAQ: IKT)

  • 12 Health Care Stocks Moving In Friday's Intraday Session

  • Avi Kapoor

    Why Tesla Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

  • Avi Kapoor

    Dow Surges 350 Points; US Crude Oil Stocks Increase

Similar companies

Companies in the same industry as Inhibikase Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.